64 related articles for article (PubMed ID: 27980026)
1. Correction: SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
Clin Cancer Res; 2016 Dec; 22(24):6302. PubMed ID: 27980026
[No Abstract] [Full Text] [Related]
2.
Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
[TBL] [Abstract][Full Text] [Related]
3. Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
Tehfe M; Dowden S; Kennecke H; El-Maraghi R; Lesperance B; Couture F; Letourneau R; Liu H; Romano A
Adv Ther; 2017 Jan; 34(1):277-279. PubMed ID: 27885491
[No Abstract] [Full Text] [Related]
4. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer.
Neesse A; Michl P; Tuveson DA; Ellenrieder V
Z Gastroenterol; 2014 Apr; 52(4):360-6. PubMed ID: 24687799
[TBL] [Abstract][Full Text] [Related]
5. The winning formulation: the development of paclitaxel in pancreatic cancer.
Ma WW; Hidalgo M
Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
[TBL] [Abstract][Full Text] [Related]
6. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
7. Taxanes: impact on pancreatic cancer.
Chiorean EG; Von Hoff DD
Anticancer Drugs; 2014 May; 25(5):584-92. PubMed ID: 24463484
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer.
Schneeweiss A; Seitz J; Smetanay K; Schuetz F; Jaeger D; Bachinger A; Zorn M; Sinn HP; Marmé F
Anticancer Res; 2014 Nov; 34(11):6609-15. PubMed ID: 25368265
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancer.
Colomer R
Womens Health (Lond); 2005 Nov; 1(3):323-9. PubMed ID: 19803874
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant Chemotherapy after Surgery for Pancreatic Cancer].
Furuse J
Gan To Kagaku Ryoho; 2016 Feb; 43(2):160-4. PubMed ID: 27067680
[TBL] [Abstract][Full Text] [Related]
11. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
12. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation of NAB-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for The Management of Metastatic Pancreatic Cancer in Greece.
Fragoulakis V; Papakostas P; Pentheroudakis G; Dervenis C; Maniadakis N
Value Health; 2014 Nov; 17(7):A632. PubMed ID: 27202246
[No Abstract] [Full Text] [Related]
14. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
Wagner LM; Yin H; Eaves D; Currier M; Cripe TP
Pediatr Blood Cancer; 2014 Nov; 61(11):2096-8. PubMed ID: 24753077
[TBL] [Abstract][Full Text] [Related]
15. Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2016 Feb; 17():63. PubMed ID: 26841937
[No Abstract] [Full Text] [Related]
16. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
[TBL] [Abstract][Full Text] [Related]
17. SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study.
Sinn M; Sinn BV; Striefler JK; Lindner JL; Stieler JM; Lohneis P; Bischoff S; Bläker H; Pelzer U; Bahra M; Dietel M; Dörken B; Oettle H; Riess H; Denkert C
Ann Oncol; 2017 Nov; 28(11):2900. PubMed ID: 27578776
[No Abstract] [Full Text] [Related]
18. Correction: The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.
Clin Cancer Res; 2016 Nov; 22(22):5619. PubMed ID: 28151716
[No Abstract] [Full Text] [Related]
19. Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
Kaira K; Tomizawa Y; Imai H; Sakurai R; Matsuura M; Yoshii A; Ochiai M; Kotake M; Ebara T; Saitoh JI; Sunaga N; Minato K; Saito R; Hisada T
Cancer Chemother Pharmacol; 2017 Jan; 79(1):165-171. PubMed ID: 27995307
[TBL] [Abstract][Full Text] [Related]
20. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G
Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
